The updated AAP guidance “recommends programmatic consideration of providing more than 5 consecutive doses of palivizumab depending on the duration of the current RSV surge in a given region of the country.”

The master cell growth regulator mTORC1 is known to be hyperactive in colon cancer. This study shows that in mice, a low protein diet blocked mTORC1’s nutrient signaling pathway, stopping the cancer from growing and leading to increased cancer cell death.

Anthony Fauci, MD, reflects on the surprising and dramatic challenges faced by a medical specialty that was in the 1960s and up to the late ’70s predicted to be destined for obsolescence.

Versus placebo, pemafibrate yielded a more than 25% greater reduction in triglycerides, VLDL, remnant cholesterol, and apolipoprotein C-III in patients with type 2 diabetes. However, there was no reduction versus placebo in MI, ischemic stroke, need for coronary revascularization, or CV death.

A trio of posters look at clinical effectiveness fostemsavir for multidrug-resistant patients, real-world efficacy of the dolutegravir/lamivudine combination as a switch strategy, and a newer drug in the pipeline, islatravir prodrug BRII-732.

BQ.1 and BQ.1.1 together now comprise more than 50% of all COVID cases in the US. Their rapid rise – with prediction that these variants will account for more than 80% of infections by Jan. 1 – lead FDA to remove the emergency use authorization for bebtelovimab, and recommend bivalent boosters and the use of ritonavir-nirmatrelvir, remdesivir, and molnupiravir for treatment of infection.